336 results on '"Svenningsson, Anders"'
Search Results
2. Comparing the Safety and Effectiveness of Different Medicines to Treat Multiple Sclerosis – The COMBAT-MS Study
3. Disease phenotype prediction in multiple sclerosis
4. Predictors of patient-reported fatigue symptom severity in a nationwide multiple sclerosis cohort
5. Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: A Swedish cohort study
6. A comparative study of fatigue and processing speed in patients with multiple sclerosis treated with natalizumab or rituximab
7. Comparing the Safety of Medicines to Treat MS during the COVID-19 Pandemic
8. Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial
9. Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension
10. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
11. Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis diseasemodulating therapy.
12. Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study.
13. Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study
14. Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy
15. Lower risk of multiple sclerosis in patients with chronic hepatitis C: a nationwide population-based registry study
16. Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy
17. Location matters: highly divergent protein levels in samples from different CNS compartments in a clinical trial of rituximab for progressive MS
18. Targeted metabolomics of CSF in healthy individuals and patients with secondary progressive multiple sclerosis using high-resolution mass spectrometry
19. Validation of elevated levels of interleukin-8 in the cerebrospinal fluid, and discovery of new biomarkers in patients with GBS and CIDP using a proximity extension assay.
20. Serum sickness following rituximab therapy in multiple sclerosis
21. Reply to Sun et al.
22. CSF biomarkers of inflammation in trigeminal neuralgia patients operated with microvascular decompression
23. Serum neurofilament light and prediction of multiple sclerosis in clinically isolated syndrome
24. Cerebrospinal fluid concentration of Galectin-9 is increased in secondary progressive multiple sclerosis
25. Intrathecal treatment trial of rituximab in progressive MS: An open-label phase 1b study
26. Cerebrospinal fluid cytokines after autologous haematopoietic stem cell transplantation and intrathecal rituximab treatment for multiple sclerosis
27. The cerebrospinal fluid cytokine signature of multiple sclerosis: A homogenous response that does not conform to the Th1/Th2/Th17 convention
28. Cerebral microvascular injuries in severe COVID-19 infection: progression of white matter hyperintensities post-infection
29. COVID‐19 clinical outcomes and DMT of MS patients and population‐based controls
30. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis
31. Cortico-juxtacortical and periventricular lesions and MS diagnostic criteria
32. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
33. Rituximab in paediatric onset multiple sclerosis: a case series
34. Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: Commentary
35. Cerebrospinal fluid cytokines after autologous haematopoietic stem cell transplantation and intrathecal rituximab treatment for multiple sclerosis.
36. Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis
37. Rituximab versus Fingolimod after Natalizumab in Multiple Sclerosis Patients
38. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial
39. Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience
40. Effect of Treatment with Natalizumab on Ability to Work in People with Multiple Sclerosis: Productivity Gain Based on Direct Measurement of Work Capacity before and after 1 Year of Treatment
41. Metabolomics of Cerebrospinal Fluid from Healthy Subjects Reveal Metabolites Associated with Ageing
42. The Effect of Different National Treatment Strategies on Disability Outcome in Relapsing-Remitting Multiple Sclerosis: A Propensity Score Adjusted Comparison between Denmark and Sweden
43. Additional file 2 of Location matters: highly divergent protein levels in samples from different CNS compartments in a clinical trial of rituximab for progressive MS
44. Additional file 1 of Location matters: highly divergent protein levels in samples from different CNS compartments in a clinical trial of rituximab for progressive MS
45. The Neurofilament Light Chain Is Not Stable in Vitro
46. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab
47. Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension
48. Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients
49. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
50. Validation of the Swedish Multiple Sclerosis Register Further Improving a Resource for Pharmacoepidemiologic Evaluations
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.